Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 in Obstructive Sleep Apnea and Obesity on PAP Therapy
NCT06994650Phase 3Active, not recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obstructive sleep apnea (OSA) and obesity comparing HRS9531 with Placebo (2 arms). Primary endpoint: Change in Apnea-Hypopnea Index at 52 weeks. Started Aug 2025; status: active, not recruiting.
02
Drugs
HRS9531
03
Conditions
obstructive sleep apnea (OSA)obesity
Beyond the preview
Go deeper on NCT06994650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06994650.